Maze Therapeutics, a clinical-stage biopharmaceutical company, announced an oversubscribed private placement of $150.0 million.
The private placement includes participation from new and existing investors, showcasing confidence in Maze Therapeutics' potential.
Proceeds from the private placement will be used to advance the development of key medicines and research programs.
Private Placement Details
4,000,002 shares of common stock at $16.25 per share and 5,231,090 pre-funded warrants purchased at $16.249 per warrant.
Investor Participation
Participation from Frazier Life Sciences, Deep Track Capital, Driehaus Capital Management, and other healthcare dedicated funds.
Use of Proceeds
Funding to advance MZE829 for APOL1-mediated kidney disease, Phase 2 trials of MZE782, research programs, and working capital.
- The oversubscribed private placement indicates strong investor interest in Maze Therapeutics' potential.
- Proceeds will significantly support the development of key medicines and research programs, enhancing the company's growth prospects.
Maze Therapeutics' successful private placement reflects investor confidence and provides crucial funding for advancing key pharmaceutical programs and research initiatives, signaling a positive outlook for the company's future growth.